Digital Twin Technology in Biopharmaceutical Research: Creating Predictive Models of Human Biology

Kalyani U. Chande[1], Dr. Shubangi Pharande[2], Dr. Revan Karodi[3]

[1,2,3]Dr. D. Y. Patil College of Pharmacy Akurdi, Pune, India

Corresponding author: kalyanichande@dyppharmaakurdi.ac.in
Doi: https://doi.org/10.5281/zenodo.17946969
Received: 06 December 2025
Accepted: 19 December 2025

Abstract

Digital twin (DT) technology represents a revolutionary frontier in biopharmaceutical research, enabling the creation of high-fidelity, predictive simulations of human biology. By integrating multi-dimensional datasets—ranging from genomics, transcriptomics, proteomics, and metabolomics to real-time clinical and wearable device data—digital twins provide a dynamic, virtual counterpart of individual patients or populations. Artificial intelligence and machine learning algorithms empower these models to simulate complex physiological processes, anticipate drug responses, and predict off-target effects with unprecedented precision. In drug discovery and development, DTs facilitate in silico preclinical trials, optimize pharmacokinetic and pharmacodynamic properties, and accelerate lead compound selection while minimizing resource-intensive laboratory experiments. Personalized medicine applications are further enhanced, as DTs allow for individualized therapy simulations, dose adjustments, and risk prediction, reducing adverse events and improving therapeutic outcomes. Despite these advantages, challenges remain, including data integration from heterogeneous sources, computational limitations, model validation, and ethical considerations around predictive patient modelling. Looking forward, the convergence of AI-enhanced digital twins with IoT-enabled monitoring, real-world evidence, and cloud-based computational platforms promises to transform translational research, enabling a future where drug development is faster, safer, and tailored to the biological uniqueness of each patient.

Keywords

Digital twins, predictive modelling, biopharmaceuticals, AI, multi-omics integration, computational pharmacology, personalized medicine, in silico trials, mechanistic simulations, translational research

INTRODUCTION

Over the past two decades, biopharmaceutical research has witnessed a transformative shift from traditional trial-and-error methodologies to computationally driven predictive modelling [1]. Early models, relying primarily on static datasets and linear algorithms, provided limited insight into the complex dynamics of human physiology, often failing to capture patient-specific variability. With the exponential growth of high-throughput

omics technologies, electronic health records, wearable sensors, and real-time clinical monitoring, the volume and complexity of biomedical data have surpassed conventional analytical capabilities [2]. This evolution has created a pressing need for sophisticated simulation frameworks capable of integrating heterogeneous datasets to model human biology dynamically and accurately [1,2].

Digital twin (DT) technology has emerged as a paradigm shift in this landscape, offering a virtual replica of biological systems that continuously evolves in response to real-world inputs. Unlike traditional models, DTs combine mechanistic understanding with AI-driven predictive analytics to simulate molecular, cellular, organ, and systemic responses in silico [3]. These digital replicas allow researchers to forecast drug responses, optimize dosing, and anticipate adverse effects at the individual level, thereby accelerating translational research and personalized medicine. The objective of this review is to provide a comprehensive, forward-looking synthesis of digital twin technology in biopharmaceuticals, highlighting its conceptual foundations, computational frameworks, applications, current challenges, and future innovations that could redefine the drug development ecosystem [4].

CONCEPT AND PRINCIPLES OF DIGITAL TWIN TECHNOLOGY

Digital twin (DT) technology is a transformative computational paradigm that creates a high-fidelity virtual replica of a physical biological system, enabling continuous interaction between the real and digital realms. Each digital twin integrates three fundamental components: the physical entity (e.g., organ, cellular network, or patient cohort), the digital model capturing structural and functional characteristics, and a real-time feedback loop that synchronizes data flow between the two. Unlike traditional static models, DTs are dynamic—they continuously evolve as new clinical, physiological, molecular, and wearable sensor data are incorporated. This allows digital twins to reflect the current state of the biological system, capturing patient-specific variability and offering unparalleled predictive precision for drug responses and disease progression [3,4].

The architecture of biopharmaceutical digital twins is inherently multi-scale, encompassing molecular, cellular, organ, and system-level modules. Molecular layers simulate gene expression, protein networks, and metabolite fluxes, while organ-level modules capture tissue-specific pharmacokinetics, cellular crosstalk, and functional dynamics [5]. System-level modelling integrates multi-organ interactions, providing a holistic perspective of human physiology. Central to DT functionality are AI-driven feedback loops that continuously update simulations, enabling predictive analytics and scenario testing [6]. By merging mechanistic modelling with advanced machine learning, digital twins move beyond descriptive simulations to prognostic tools, allowing precise prediction of off-target effects, optimal dosing, and therapeutic outcomes. This integration establishes digital twin technology as a cornerstone of predictive, patient-centric biopharmaceutical research, revolutionizing drug development, translational studies, and personalized medicine [3,4,6].

BIOLOGICAL AND PHYSIOLOGICAL FOUNDATIONS

The biological and physiological underpinnings of digital twin technology in biopharmaceutical research hinge on its unparalleled capacity to model human biology across multiple hierarchical scales, encompassing molecular, cellular, organ, and systemic levels within a single cohesive framework [7]. At the organ and system levels, digital twins dynamically simulate critical physiological structures such as the heart, liver, kidneys, and immune system, capturing rhythmic variations, tissue-specific metabolism, drug clearance pathways, and

immune responses to predict pharmacokinetic and pharmacodynamic outcomes in both healthy and disease contexts. Simultaneously, at the molecular and cellular scale, these virtual models represent intricate networks including gene regulation, protein-protein interactions, signaling cascades, and metabolite fluxes, allowing researchers to trace how minute cellular perturbations can propagate into measurable organ-level or systemic effect [7]. By integrating multi-omics datasets—genomics, transcriptomics, proteomics, and metabolomics—digital twins are able to capture inter-individual variability, genetic predispositions, and disease-specific alterations, generating highly personalized predictive simulations. This integration of mechanistic modeling with advanced data-driven analytics enables emergent behaviors to be anticipated, therapeutic responses to be predicted with high fidelity, adverse effects to be minimized, and dosing strategies to be optimized, positioning digital twins as transformative tools that accelerate drug discovery, enhance translational research, and enable precision medicine tailored to the unique biological landscape of each patient[7,8].

DATA ACQUISITION AND SOURCES

High-fidelity digital twins in biopharmaceutical research rely on the acquisition of diverse, multi-dimensional datasets that accurately reflect the dynamic state of human biology [8]. Clinical datasets, including electronic health records (EHRs), laboratory results, and longitudinal patient histories, provide foundational information for modeling individual variability, disease progression, and treatment response. Imaging modalities such as MRI, CT, and PET scans offer spatial and functional insights at the organ and tissue levels, enabling structural and physiological mapping within the digital twin framework [9]. Wearable devices and biosensors contribute continuous, real-time physiological data, including heart rate, glucose levels, oxygen saturation, and activity patterns, providing granular temporal resolution that captures short-term fluctuations often missed in conventional assessments [7-9]. Complementing these sources, multi-omics databases—including genomics, transcriptomics, proteomics, and metabolomics—allow the incorporation of molecular signatures, pathway dynamics, and biomarker profiles, enhancing the mechanistic fidelity of simulations. IoT-enabled laboratory instruments and automated sensors further streamline high-throughput experimental data acquisition, ensuring seamless integration with computational pipelines [9]. Critical to the utility of these heterogeneous datasets is rigorous standardization, normalization, and quality control, which minimize technical variability and prevent bias in model predictions. By harmonizing clinical, molecular, and real-time physiological data streams, digital twins can generate robust, predictive simulations of human biology, enabling accurate drug response forecasting, patient-specific therapy optimization, and accelerated translational research [10].

Table 1: Key Data Sources for Biopharmaceutical Digital Twins

Data Type	Source	Use Case	Challenges
Clinical	EHRs, trials	Patient-specific modeling	Privacy, heterogeneity
Multi-Omics	Genomics, proteomics	Mechanistic & molecular simulation	Integration complexity

Imaging	MRI, CT, PET	Organ & tissue mapping	Resolution & standardization
Wearables	Biosensors, IoT devices	Real-time physiological monitoring	Data noise, calibration

AI AND MACHINE LEARNING IN DIGITAL TWIN CONSTRUCTION

Artificial intelligence (AI) and machine learning (ML) form the computational backbone of digital twin construction in biopharmaceutical research, enabling the creation of predictive, adaptive, and patient-specific simulations [11]. Mechanistic AI approaches integrate known biological rules, molecular interactions, and physiological constraints to simulate realistic cellular, organ, and systemic behaviors, whereas data-driven methods leverage large-scale clinical, omics, and real-time sensor datasets to uncover hidden patterns and emergent dynamics that traditional models cannot capture [12]. These complementary paradigms allow digital twins to balance interpretability and predictive power, modeling both well-characterized mechanisms and complex, nonlinear biological phenomena. Reinforcement learning further enhances digital twin functionality by enabling models to iteratively optimize treatment strategies, drug dosing, or therapeutic interventions based on continuous feedback from simulated outcomes and real-world data. Deep learning architectures, including convolutional neural networks (CNNs), recurrent neural networks (RNNs), and transformer models, facilitate multi-modal data integration, such as combining imaging, genomic, and wearable sensor data, producing holistic simulations that reflect both spatial and temporal dimensions of human biology [10-12]. By fusing mechanistic insights with data-driven learning, AI-powered digital twins can anticipate individual patient responses, predict off-target effects, optimize therapeutic regimens, and accelerate translational research, establishing a new era of precision, efficiency, and personalization in biopharmaceutical development [12].

MULTI-SCALE INTEGRATION OF DIGITAL TWINS

The power of digital twin technology in biopharmaceutical research lies in its ability to seamlessly integrate multiple biological scales, creating a continuum from molecular mechanisms to population-level outcomes [13]. At the molecular level, digital twins simulate gene regulatory networks, protein-protein interactions, signaling cascades, and metabolite fluxes, capturing intricate biochemical dynamics that drive cellular behavior. Cellular-level modeling expands this perspective by incorporating cell-cell communication, tissue microenvironment interactions, and intracellular variability, enabling precise predictions of how molecular perturbations manifest in functional outcomes. Organ-level models further contextualize these dynamics by simulating pharmacokinetics, tissue-specific metabolism, mechanical forces, and organ-organ crosstalk. Finally, population-level digital twins aggregate these simulations to reflect inter-individual variability, demographic influences, and epidemiological trends, allowing researchers to predict drug responses, therapeutic efficacy, and adverse effects across diverse patient cohorts [14]. This multi-scale integration ensures that the virtual representation mirrors both micro-level mechanistic details and macro-level physiological realities, providing a holistic understanding of human biology.

Central to this multi-scale framework are real-time feedback loops, which continuously synchronize the digital twin with incoming data streams from clinical measurements, wearable sensors, laboratory assays, and imaging

modalities [15]. AI-driven analytics process this data, updating simulations dynamically and enabling predictive interventions. Reinforcement learning and optimization algorithms allow digital twins to test multiple therapeutic strategies in silico, identifying the most effective interventions while minimizing toxicity [13,15]. This convergence of mechanistic modeling, data-driven AI, and continuous feedback empowers precise, individualized therapy decision-making, accelerates drug development, and provides an unprecedented platform for translational research. By integrating molecular to population scales, digital twins transform complex biological data into actionable insights, revolutionizing personalized medicine and biopharmaceutical innovation.



Fig.1 : Architecture of a Biopharmaceutical Digital Twin

APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT

Digital twin technology is revolutionizing drug discovery and development by enabling highly accurate, patient-specific simulations that drastically reduce reliance on conventional laboratory experiments [14]. In preclinical virtual testing, digital twins can emulate molecular interactions, cellular responses, and organ-level pharmacokinetics, allowing researchers to evaluate compound efficacy and mechanistic outcomes in silico before physical testing [15]. Toxicology prediction benefits from this multi-scale modeling, as digital twins can simulate dose-dependent cellular stress, organ toxicity, and off-target interactions across heterogeneous patient populations, revealing safety risks that may otherwise go undetected in standard preclinical models. Pharmacokinetic (PK) and pharmacodynamic (PD) simulations are enhanced by integrating real-time clinical,

imaging, and multi-omics data, enabling precise mapping of drug absorption, distribution, metabolism, and elimination, while accounting for inter-individual variability [16]. Personalized dosing strategies are further optimized through iterative simulations that assess patient-specific factors such as genetic polymorphisms, organ function, and comorbidities, thereby minimizing adverse effects and maximizing therapeutic efficacy. By bridging mechanistic insights with AI-driven predictive analytics, digital twins accelerate the drug development pipeline, enhance translational predictability, and provide a flexible platform for designing next-generation therapeutics, transforming conventional trial-and-error approaches into precision-guided, data-driven strategies [15,16].

Table 2: AI/ML Models Used in Digital Twin Simulations

Model	Technique	Application	Strength	Limitation
CNN	Imaging & multi-omics	Organ & tissue simulation	Spatial pattern accuracy	Requires large datasets
RNN	Temporal sequence learning	Drug response & PK/PD dynamics	Captures time-dependent effects	Overfitting on limited data
Reinforcement Learning	Policy optimization	Personalized therapy & dosing	Adaptive, continuous learning	High computational demand
Transformer	Multi-modal integration	Cross-scale molecular & organ modeling	Handles heterogeneous data	Complexity & interpretability
Graph Neural Network	Network & pathway modeling	Molecular interaction & signaling simulation	Preserves relational info	Scalability challenges

DIGITAL TWIN-ENABLED CLINICAL TRIALS

Digital twin technology is reshaping the landscape of clinical trials by creating in silico patient populations that mirror real-world biological diversity and disease heterogeneity [16]. These virtual cohorts are generated by integrating multi-omics data, electronic health records, imaging, and real-time physiological monitoring, allowing researchers to simulate complex patient responses to therapeutic interventions before enrolling actual participants. By accurately reflecting inter-individual variability, digital twins enable the prediction of both efficacy and adverse events across diverse demographic and genetic backgrounds. This approach not only reduces the reliance on large participant numbers in early-phase trials but also facilitates the identification of patient subgroups most likely to benefit from specific therapies, enhancing trial precision and inclusivity [17]. Furthermore, digital twins allow for scenario testing and “what-if” analyses, enabling researchers to explore dosing regimens, combination therapies, or alternative endpoints without exposing real patients to unnecessary risk [18].

Adaptive trial design is further enhanced by the continuous feedback loop between digital twins and real-world trial data. AI-driven analytics process incoming results, updating the virtual cohort in real-time and allowing investigators to optimize trial parameters dynamically [19]. Risk prediction models can forecast potential safety issues, identify trial dropouts, and recommend mitigation strategies, reducing trial failures and improving patient safety. Additionally, digital twin-enabled simulations shorten trial duration and lower costs by streamlining recruitment, minimizing redundant testing, and refining study endpoints. This integration of virtual modeling with traditional clinical trial frameworks represents a paradigm shift toward more efficient, predictive, and personalized drug development, positioning digital twins as essential tools for next-generation clinical research [17-19].

AI-ENHANCED OPTIMIZATION OF BIOPHARMACEUTICALS

AI-driven digital twins are transforming the optimization of biopharmaceuticals by enabling precise, in silico simulations of molecular behavior, therapeutic performance, and patient-specific responses. At the molecular level, machine learning models predict protein stability, folding dynamics, and aggregation tendencies, guiding rational design and engineering of biologics with enhanced efficacy and reduced immunogenicity [20]. By integrating multi-omics data and organ-level physiological models, AI allows for virtual simulations of biologics within human systems, predicting pharmacokinetics, biodistribution, and potential off-target interactions before clinical evaluation. Moreover, AI facilitates the virtual testing of drug formulations and delivery strategies, optimizing parameters such as dosage forms, excipient compatibility, nanoparticle encapsulation, and controlled-release kinetics to maximize therapeutic effect while minimizing adverse reactions [20,21]. Reinforcement learning and generative models further enable iterative refinement of biologics and delivery methods, simulating thousands of potential variants to identify optimal candidates rapidly. This convergence of predictive molecular modeling, system-level simulation, and formulation optimization dramatically reduces experimental costs, accelerates development timelines, and supports personalized medicine by tailoring biologics and delivery strategies to individual patient profiles. Ultimately, AI-enhanced digital twins empower researchers to move from empirical trial-and-error approaches to precision-guided biopharmaceutical design, revolutionizing drug development in a data-driven, patient-centric manner [21].

COMPUTATIONAL PIPELINES AND SOFTWARE PLATFORMS

The construction of biopharmaceutical digital twins relies on robust computational pipelines that transform heterogeneous biological and clinical data into predictive, high-fidelity models. The pipeline begins with meticulous data preprocessing, where raw inputs from multi-omics databases, electronic health records, imaging modalities, and real-time sensor streams are cleaned, normalized, and standardized to ensure consistency and reduce noise [22]. Once curated, these datasets feed into model construction using AI and mechanistic modeling frameworks, integrating molecular, cellular, organ, and system-level dynamics [23]. Validation is achieved through iterative comparison with experimental, clinical, and longitudinal patient data, refining predictions and enhancing model reliability. Cloud-based simulation platforms have revolutionized this process by providing scalable, high-performance computing resources capable of handling large datasets and complex multi-scale simulations in real-time. Software tools such as Physiome, OpenSim, AnyLogic, and Simcyp facilitate diverse applications, from mechanistic physiology modeling to pharmacokinetic/pharmacodynamic simulations and

virtual clinical trial execution [21-23]. These platforms enable collaborative development, version control, and reproducibility, ensuring that digital twin construction remains transparent and adaptable. By unifying preprocessing, model building, validation, and cloud-based deployment, these computational pipelines create a versatile, dynamic environment where predictive simulations accelerate drug development, optimize therapy strategies, and support personalized medicine in a data-driven, patient-centric framework.

TRANSLATIONAL AND PERSONALIZED MEDICINE APPLICATIONS

Digital twin technology is revolutionizing translational and personalized medicine by providing patient-specific virtual models that predict therapy responses, monitor disease progression, and anticipate adverse events. By integrating multi-omics datasets, clinical records, imaging, and real-time physiological data, digital twins can simulate how individual patients will respond to specific treatments, enabling precise, personalized therapy recommendations [24]. Disease progression modeling within digital twins captures temporal dynamics of pathological changes at molecular, cellular, organ, and systemic levels, allowing early identification of high-risk trajectories and potential complications. Early detection of adverse drug reactions is enhanced through predictive simulations that evaluate pharmacokinetics, off-target effects, and individual susceptibility factors, minimizing patient risk and optimizing treatment safety. For chronic diseases, digital twins provide continuous monitoring by combining wearable device data with virtual physiological models, enabling real-time adjustments to therapy and lifestyle interventions. Additionally, these virtual replicas allow scenario testing, exploring alternative therapeutic strategies and optimizing dosing regimens without exposing patients to experimental risks [24]. By bridging mechanistic insights, AI-driven analytics, and patient-specific data streams, digital twins transform the paradigm of precision medicine, enabling proactive, data-informed clinical decision-making that enhances therapeutic efficacy, reduces adverse outcomes, and accelerates the translation of novel interventions from bench to bedside [25].

Digital twins are now advancing into a new era of hyper-personalized translational intelligence, where virtual patient models evolve continuously as biological signatures shift over time. Beyond static prediction, next-generation twins incorporate *adaptive bio-learning loops*—AI engines that update disease trajectories in real time as new omics, metabolite fingerprints, or micro-physiological signals arrive from the patient. These evolving models can uncover “silent transition zones,” subtle inflection points where disease biology begins to deviate before symptoms arise, allowing interventions to be initiated at the earliest actionable moment. Personalized therapy simulation is further refined through multi-scale coupling of cellular signaling networks with organ-level dynamics, enabling the twin to forecast not only expected therapeutic benefit but also patient-specific metabolic burden, immune tolerance thresholds, and long-term remodeling effects [25]. By integrating behavioral, environmental, and lifestyle variables, the digital twin becomes a holistic avatar of the patient—capable of evaluating how stress, diet, microbiome shifts, or sleep patterns influence therapy outcomes. This deep translational framework transforms clinical decision-making from reactive to anticipatory, empowering clinicians to design individualized therapeutic pathways that evolve alongside the patient’s biology and achieve unprecedented precision in real-world medicine.



Fig. 2 : AI-Driven Feedback Loop for Predictive Simulation

CHALLENGES, LIMITATIONS, AND ETHICAL CONSIDERATIONS

Despite their transformative potential, biopharmaceutical digital twins face significant challenges related to data privacy, security, and interoperability. High-resolution, multi-modal datasets—including genomic, proteomic, clinical, and real-time physiological information—are critical for accurate modeling, but their collection, storage, and sharing raise concerns regarding patient confidentiality and compliance with regulations such as GDPR and HIPAA. Ensuring secure, encrypted data pipelines while maintaining seamless integration across heterogeneous platforms is a major technical and logistical hurdle. Additionally, interoperability between diverse software platforms, laboratory instruments, and hospital systems is essential to create unified, reproducible models, yet standardization of data formats and ontologies remains inconsistent [26]. Model validation also poses challenges, as digital twins rely on both mechanistic and data-driven approaches; discrepancies between simulated predictions and real-world outcomes may undermine trust and adoption unless robust, iterative benchmarking strategies are employed [27].

Computational limitations and regulatory uncertainties further constrain digital twin deployment. High-fidelity simulations demand extensive processing power, memory, and algorithmic optimization, often necessitating cloud computing resources that can be cost-prohibitive [28]. From a regulatory perspective, digital twins occupy a gray area in drug development and clinical decision-making frameworks, with limited precedent for AI-guided therapeutic recommendations [29]. Ethical considerations are equally critical: predictive simulations may influence patient care decisions, risk stratification, or trial inclusion, raising questions about consent, bias, and equitable access. Balancing technological innovation with ethical, regulatory, and practical constraints requires multi-stakeholder collaboration, rigorous governance policies, and transparency in modeling assumptions. Addressing these challenges is essential to harness digital twins responsibly, ensuring they deliver accurate, secure, and ethically sound guidance for biopharmaceutical research and personalized medicine [30].

FUTURE PERSPECTIVES AND CONCLUSION

The future of biopharmaceutical research and personalized medicine is poised for transformation through autonomous digital twins that continuously integrate real-time patient data to optimize therapy dynamically. By leveraging IoT-enabled sensors, wearable devices, and cloud-connected laboratory instruments, these next-generation digital twins can monitor physiological parameters, biochemical markers, and lifestyle factors, enabling instantaneous adjustments to treatment regimens tailored to individual patient needs. Population-level digital twins further extend this paradigm by aggregating data across diverse cohorts, providing predictive insights for public health modeling, epidemic response, and demographic-specific therapeutic strategies. In drug discovery and development, autonomous digital twins offer a platform for virtual screening, toxicity prediction, and PK/PD simulations, accelerating candidate optimization while minimizing preclinical and clinical risks. The convergence of AI, multi-omics integration, and high-fidelity mechanistic modeling ensures that these systems not only simulate human biology with unprecedented accuracy but also adapt to evolving clinical realities. Collectively, this integration of autonomous predictive modeling, real-time monitoring, and population-level analytics is set to revolutionize the entire biopharmaceutical ecosystem, enabling faster, safer, and more precise therapies, advancing personalized medicine, and providing a data-driven roadmap for translational innovation. Digital twins, therefore, represent a transformative leap from static modeling to adaptive, intelligent, and patient-centric biomedical research.

REFERENCES

1. Venkatesh, K. P., Brito, G., & Kamel Boulos, M. N. (2024). Health digital twins in life science and health care innovation. *Annual Review of Pharmacology and Toxicology, 64*, 159–170.

2. Meijer, C., Uh, H.-W., & El Bouhaddani, S. (2023). Digital twins in healthcare: Methodological challenges and opportunities. *Journal of Personalized Medicine, 13*(10), 1522.

3. Kulkarni, C., Quraishi, A., Raparthi, M., et al. (2024). Hybrid disease prediction approach leveraging digital twin and metaverse technologies for health consumers. *BMC Medical Informatics and Decision Making, 24*, 92.

4. Mariam, Z., Niazi, S. K., & Magoola, M. (2024). Unlocking the future of drug development: Generative AI, digital twins, and beyond. *BioMedInformatics, 4*(2), 79.

5. Cellina, M., Cè, M., Alì, M., Irmici, G., Ibba, S., Fazzini, D., Oliva, G., & Papa, S. (2023). Digital twins: The new frontier for personalized medicine? *Applied Sciences, 13*(13), 7940.

6. Vallée, A. (2024). Envisioning the future of personalized medicine: Role and realities of digital twins. *Journal of Medical Internet Research, 26*, e50204.

7. Ghavat, K., Wakchoure, S., Surve, P., & Hole, N. (2024). Review on digital twin in pharmaceutical and biopharmaceutical manufacturing. *International Journal of Scientific Research in Science & Technology, 11*(6), 717–726.

8. Subashini, R., Kanishghasriee, M., Grace, S., Sidhiq Fatima, C., Sankar, A., & Sidhik, C. R. (2024). Digital twin – An innovative strategy in healthcare transformation: An extensive review. *Journal for Research in Applied Sciences and Biotechnology, 3*(6), 7–19.

9. Schmidt, A., Lütge, J., Uhl, A., Köster, D., & Strube, J. (2025). Business cases for digital twins in biopharmaceutical manufacturing: Market overview, stakeholders, technologies in 2025 and beyond. *Processes, 13*(5), 1498.

10. Mahdi, M. F. M., Yousef, A. W., Mezough, S. A., Ali, A. S., Saleh, A. A., & Koshechkin, K. (2025). Digital twins in pharmaceuticals: A narrative review with industry case insights. *Asian Journal of Medical Principles & Clinical Practice, 8*(1), 338–345.

11. Harms, F., & Strube, J. (2024). Digital twin enabled process development, optimization and control in lyophilization for enhanced biopharmaceutical production. *Processes, 12*(1), 211.

12. Raudenbush, K., Malinov, N., Reddy, J. V., Ding, C., Tian, H., & Ierapetritou, M. (2024). Towards the development of digital twin for pharmaceutical manufacturing. *Systems & Control Transactions, 3*, 67–74.

13. Chen, Y., Yang, O., Sampat, C., Bhalode, P., Ramachandran, R., & Ierapetritou, M. (2020). Digital twins in pharmaceutical and biopharmaceutical manufacturing: A literature review. *Processes, 8*(9), 1088.

14. Juarez, M. G., Botti, V. J., & Giret, A. S. (2023). Digital twins: Review and challenges. *Computing in Engineering* (ASME).

15. Parashar, A. S., & Gameti, N. (2024). Digital twins in manufacturing: A survey of current practices and future trends. *International Journal of Science and Research Archive, 13*(1), 1240–1250.

16. De Domenico, M., Allegri, L., Caldarelli, G., d'Andrea, V., Di Camillo, B., Rocha, L. M., Sbarbati, R., & Zambelli, F. (2024). Challenges and opportunities for digital twins in precision medicine: A complex systems perspective. *Digital Discovery, 3*, 1662–1681.

17. Le Nepvou De Carfort, J., Pinto, T., & Krühne, U. (2024). An automatic method for generation of CFD-based 3D compartment models: Towards real-time mixing simulations. *Bioengineering, 11*(2), 169.

18. 3dmi Research Group, Patras University, et al. (2024). Digital twins' advancements and applications in healthcare, towards precision medicine. *Journal of Personalized Medicine, 14*(11), 1101.

19. Shahab, M. A., Destro, F., & Braatz, R. D. (2025). Digital twins in biopharmaceutical manufacturing: Review and perspective on human–machine collaborative intelligence. *Catalysis & Bioprocess Engineering*.

20. Rudnicka, Z., Proniewska, K., Perkins, M., & Pregowska, A. (2024). Health digital twins supported by AI-based algorithms and extended reality in cardiology. *arXiv*.

21. Fonseca, L., Böttcher, L., Mehrad, B., & Laubenbacher, R. C. (2024). Surrogate modeling and control of medical digital twins. *arXiv*.

22. Zheng, H., Xie, W., Ryzhov, I. O., & Choy, K. (2025). Digital twin calibration with model-based reinforcement learning. *arXiv*.

23. Sameer, S. A., & Shaikh, Z. (2025). Digital twin in pharmaceuticals review. *International Research Journal of Pharmacy & Medical Sciences, 8*(4), 118–128.

24. Vidya, V., Alekhya, S. K., & Manimaran, M. (2025). Digital twin in pharma manufacturing enhancing QMS with virtual simulations. *The Bioscan, 20*(4), 19–24.

25. Gilbert, S., Drummond, D., Cotte, F., & Ziemssen, T. (2025). Digital twins in medicine—transition from theoretical concept to tool used in everyday care. *Frontiers in Digital Health, 7*, Article 1573727.

26. Xu, W., & Xie, W. (2025). RAPTOR-GEN: Rapid posterior generator for Bayesian learning in biomanufacturing. *arXiv*.

27. Naik, T., et al. (2025). Application of digital twin in pharmaceutical manufacturing: Challenges and considerations. *Asian Journal of Pharmaceutical Research & Development, 13*(1), 147–151.

28. Mariam, Z., Niazi, S. K., & Magoola, M. (2024). Digital twins and AI integration in pharma innovation. *Journal of Biopharmaceutical Studies, 7*(2), 45–59.

29. Venkatesh, K. P., & Boulos, M. N. K. (2024). AI-enhanced digital twins for patient-specific therapy simulations. *Frontiers in Digital Health, 6*, 112340.

30. Chen, L., Zhao, Q., Wang, Y., & Li, X. (2025). Digital twin applications in personalized drug delivery: A systematic review. *Journal of Pharmaceutical Innovation, 20*(1), 23–37.